1. MIMS. Ergotamine. 2018 https://www.mims.com/indonesia/drug/info/ergotaminee/?type=brief&mtype=generic
5. Tfelt-Hansen, P. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain, 2000. 123(1): 9–18.doi:10.1093/brain/123.1.9
9. B.G. Katzung, in Basic & Clinical pharmacology, ed B.G. Katzung dan A.J. Trevor, Mc-Graw Hill, New York, 2015, 16.
11. Medscape. Ergotamine (Rx). 2018. https://reference.medscape.com/drug/ergomar-ergotaminee-343027.
14. Aydogan K, Karadogan SK, Adim SB, Tunali S. Pityriasis Rosea-Like Eruption due to Ergotamine: A Case Report. The Journal of Dermatology, 2005. 32(5): 407–409. doi:10.1111/j.1346-8138.2005.tb00917.x
15. Uptodate. Ergotamine and caffeine: Drug information. 2018. https://www.uptodate.com/contents/ergotaminee-and-caffeine-drug-information.
16. Rostoff P, Gajos G, Latacz P, Wozniczko M, Matysek J, Piwowarska W. Ergotamine-induced cardiovascular toxicity: mechanisms and clinical significance. International Journal of Cardiology, 2010. 141(1): 111–114. doi:10.1016/j.ijcard.2008.11.102
17. Novartis. Product monograph Cafergot. 2012.
19. Molkara AM, Abou-Zamzam AM, Teruya TH, Bianchi C, Killeen JD. Chronic Ergot Toxicity Presenting with Bilateral External Iliac Artery Dissection and Lower Extremity Rest Pain. Annals of Vascular Surgery, 2006. 20(6): 803–808. doi:10.1007/s10016-006-9133-9
20. Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine : a case report and review of literature. The J of Heart Valve Dis, 1996. 5(2): 235-237.